BMS 986458
Alternative Names: BCL6 LDD; BMS-986458Latest Information Update: 18 Jun 2025
At a glance
- Originator Bristol-Myers Squibb
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Non-Hodgkin's lymphoma
Most Recent Events
- 12 Jun 2025 Efficacy and adverse events data from a phase I/II trial in Non-Hodgkin's lymphoma released by Bristol-Myers Squibb
- 07 Dec 2024 Pharmacodynamics data from a preclinical trial in Non-Hodgkin's lymphoma presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024)
- 20 Sep 2024 Phase-I/II clinical trials in Non-Hodgkin's lymphoma (Combination therapy, Second-line therapy or greater) in USA, France, Germany, Netherlands, Spain, Switzerland (PO) (NCT06090539)